Tracy M Layne1,2, Stephanie J Weinstein2, Barry I Graubard2, Xiaomei Ma1,3, Susan T Mayne1,3, Demetrius Albanes2. 1. Chronic Disease Epidemiology Department, Yale School of Public Health, New Haven, Connecticut. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. 3. Yale Comprehensive Cancer Center, Yale University, New Haven, Connecticut.
Abstract
BACKGROUND: Few studies have prospectively examined the relationship between vitamin D status and prostate cancer risk in black men, a group at high risk for both low vitamin D status and prostate cancer. METHODS: Among black men in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we identified 226 prostate cancer cases and 452 controls matched on age at randomization (±5 years), date of blood draw (±30 days), calendar year of cohort entry, and time since baseline prostate cancer screening (±1 year). Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between serum 25-hydroxyvitamin D [25(OH)D], vitamin D binding protein (DBP), the 25(OH)D:DBP molar ratio, and prostate cancer risk. RESULTS: Serum 25(OH)D was not associated with overall prostate cancer (Q4 vs Q1: OR, 0.73; 95% CI, 0.40-1.33; P for trend = .25), although there were apparent inverse associations for nonaggressive disease (global P = .03, clinical stage I/II, and Gleason score <7) and among men ≥62 years old (P for interaction = .04) that were restricted to Q3. Interestingly, serum DBP was significantly inversely associated with prostate cancer risk (Q4 vs Q1: OR, 0.45; 95% CI, 0.20-1.00; P for trend = .03), whereas the 25(OH)D:DBP molar ratio was not. Results were similar when we mutually adjusted for 25(OH)D and DBP, and we found no evidence of interaction between the two. CONCLUSION: Our study suggests higher (versus lower) circulating DBP may be independently associated with a decreased prostate cancer risk in black men independent of 25(OH)D status. Cancer 2017;123:2698-704.
BACKGROUND: Few studies have prospectively examined the relationship between vitamin D status and prostate cancer risk in black men, a group at high risk for both low vitamin D status and prostate cancer. METHODS: Among black men in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we identified 226 prostate cancer cases and 452 controls matched on age at randomization (±5 years), date of blood draw (±30 days), calendar year of cohort entry, and time since baseline prostate cancer screening (±1 year). Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between serum 25-hydroxyvitamin D [25(OH)D], vitamin D binding protein (DBP), the 25(OH)D:DBP molar ratio, and prostate cancer risk. RESULTS: Serum 25(OH)D was not associated with overall prostate cancer (Q4 vs Q1: OR, 0.73; 95% CI, 0.40-1.33; P for trend = .25), although there were apparent inverse associations for nonaggressive disease (global P = .03, clinical stage I/II, and Gleason score <7) and among men ≥62 years old (P for interaction = .04) that were restricted to Q3. Interestingly, serum DBP was significantly inversely associated with prostate cancer risk (Q4 vs Q1: OR, 0.45; 95% CI, 0.20-1.00; P for trend = .03), whereas the 25(OH)D:DBP molar ratio was not. Results were similar when we mutually adjusted for 25(OH)D and DBP, and we found no evidence of interaction between the two. CONCLUSION: Our study suggests higher (versus lower) circulating DBP may be independently associated with a decreased prostate cancer risk in black men independent of 25(OH)D status. Cancer 2017;123:2698-704.
Authors: C J Paller; Y M Kanaan; D A Beyene; T J Naab; R L Copeland; H L Tsai; N F Kanarek; T S Hudson Journal: Prostate Date: 2015-06-05 Impact factor: 4.104
Authors: Amanda Black; Wen-Yi Huang; Patrick Wright; Tom Riley; Jerome Mabie; Sunitha Mathew; Lawrence Ragard; Sigurd Hermansen; Kelly Yu; Paul Pinsky; Philip C Prorok; Neal D Freedman; Robert N Hoover Journal: Rev Recent Clin Trials Date: 2015
Authors: Adam B Murphy; Yaw Nyame; Iman K Martin; William J Catalona; Courtney M P Hollowell; Robert B Nadler; James M Kozlowski; Kent T Perry; Andre Kajdacsy-Balla; Rick Kittles Journal: Clin Cancer Res Date: 2014-05-01 Impact factor: 12.531
Authors: Lisa Gallicchio; Kathy J Helzlsouer; Wong-Ho Chow; D Michal Freedman; Susan E Hankinson; Patricia Hartge; Virginia Hartmuller; Chinonye Harvey; Richard B Hayes; Ronald L Horst; Karen L Koenig; Laurence N Kolonel; Francine Laden; Marjorie L McCullough; Dominick Parisi; Mark P Purdue; Xiao-Ou Shu; Kirk Snyder; Rachael Z Stolzenberg-Solomon; Shelley S Tworoger; Arti Varanasi; Jarmo Virtamo; Lynne R Wilkens; Yong-Bing Xiang; Kai Yu; Anne Zeleniuch-Jacquotte; Wei Zheng; Christian C Abnet; Demetrius Albanes; Kimberly Bertrand; Stephanie J Weinstein Journal: Am J Epidemiol Date: 2010-06-18 Impact factor: 4.897
Authors: Kalvin J Gregory; Bing Zhao; Diane R Bielenberg; Sami Dridi; Jason Wu; Weihua Jiang; Bin Huang; Steven Pirie-Shepherd; Michael Fannon Journal: PLoS One Date: 2010-10-18 Impact factor: 3.240
Authors: E H Corder; H A Guess; B S Hulka; G D Friedman; M Sadler; R T Vollmer; B Lobaugh; M K Drezner; J H Vogelman; N Orentreich Journal: Cancer Epidemiol Biomarkers Prev Date: 1993 Sep-Oct Impact factor: 4.254
Authors: Susan E Steck; Lenore Arab; Hongmei Zhang; Jeannette T Bensen; Elizabeth T H Fontham; Candace S Johnson; James L Mohler; Gary J Smith; Joseph L Su; Donald L Trump; Anna Woloszynska-Read Journal: PLoS One Date: 2015-04-28 Impact factor: 3.240
Authors: Chen Yuan; Irene M Shui; Kathryn M Wilson; Meir J Stampfer; Lorelei A Mucci; Edward L Giovannucci Journal: Int J Cancer Date: 2018-12-06 Impact factor: 7.396
Authors: Stephanie J Weinstein; Alison M Mondul; Tracy M Layne; Kai Yu; Jiaqi Huang; Rachael Z Stolzenberg-Solomon; Regina G Ziegler; Mark P Purdue; Wen-Yi Huang; Christian C Abnet; Neal D Freedman; Demetrius Albanes Journal: JNCI Cancer Spectr Date: 2022-03-02
Authors: Swathi Ramakrishnan; Susan E Steck; Lenore Arab; Hongmei Zhang; Jeannette T Bensen; Elizabeth T H Fontham; Candace S Johnson; James L Mohler; Gary J Smith; L Joseph Su; Anna Woloszynska Journal: Prostate Date: 2019-05-11 Impact factor: 4.012